Amid uncertainty over the future of clinical trials in the UK, the MHRA announces that it will streamline the process of running trials to make the country a more ‘attractive destination’.
Breath biopsy specialist, Owlstone Medical, has entered into a research agreement with biotech company, Bicycle Therapeutics plc, to access its bicyclic peptide technology.
The company launches its new ZS300 sensor, ZB200 bridge and Android sensor discovery app, which will be made available for use with the supply chains of the pharma and food industries.
Challenging target profiles can be targeted more efficiently than traditional drug discovery using Exscientia’s AI-driven precision design platform, its CEO says.
Non-clinical research has been published about roginolisob, iOnctura’s non-ATP competitive alloseteric modulator of PI3Kδ, for the potential treatment of patients with solid and hematological tumors.
Earlier this year, Akorn Pharmaceuticals fell into bankruptcy, and now an alliance of stakeholders have released a report outlining potential supply disruption to a number of medications.
Positive data from a phase 2 clinical trial has proven the general mechanism of action of SK channel inhibition for treatment of atrial fibrillation (AF), an abnormal heart rhythm.
Medicine developer, CatSci Ltd announced yesterday (March 15) that it has formed a new partnership with AGC Pharma Chemicals, a small molecule Contract Development and Manufacturing Organisation (CDMO).
After completing the acquisition of Aveo, the Korean chemical company wants its subsidiary to become a global leader in the therapeutic area within five years.
Poolbeg Pharma plc has been granted a patent by the US Patent and Trademark Office (USPTO) for ways of treating hypercytokinaemia using a small molecule immunomodulator.
Small molecule drug, Niraparib combined with abiraterone acetate (AA) and prednisone (P) significantly reduces the risk of disease progression, or death, in patients with a type of prostate cancer, a consultant in Spain has said.
Two men have been jailed and another handed a suspended sentence, for selling more than three million doses of prescription-only and unlicensed medicines, including controlled medicines.
Charité – Universitätsmedizin Berlin, one of Europe’s largest university hospitals is collaborating with UK-based Exscientia to make use of an artificial intelligence-driven precision medicine platform in haematological cancers.
The company is using a ‘lab-in-the-loop’ process to advance the drug discovery process, and stated that opening a new lab space represents a step forward on its path to ‘transform drug discovery’.
Children in Europe living with HIV are on course to receive a once-daily treatment after EU marketing authorisation (EMA) was given to ViiV Healthcare’s Triumeq PD.
A survey conducted to understand whether supply issues over amoxicillin have persisted in the US found that an overwhelming majority of pharmacists are still struggling to source the commonly-used antibiotic.
The company announces an addition to its portfolio of drug delivery devices, with its pen injector platform that is described as being more affordable to produce.
Hataali has introduced a new version of its blockchain-based advanced therapy platform to address one of the key supply chain challenges faced by contract manufacturers and pharma companies today.
The company announces the submission of a 510(k) premarket notification application for its investigational inhaled nitric oxide delivery system for its INOmax gas product.
Researchers from the University of California San Diego tested whether algae could improve the delivery of antibiotics to treat cases of bacterial pneumonia.
TransCelerate BioPharma continues to work towards “bringing new medicines to patients faster”. We caught up with the organization’s CEO to hear about its main achievements over the past decade and learn about what comes next.
Pfizer and CytoReason have been partnered on artificial intelligence and machine learning technologies for drug discovery and development since 2019. The latest deal brings the companies closer.
Impel Pharmaceuticals’ Trudhesa treatment, paired with its Precision Olfactory Delivery system, reportedly shows promise to women suffering from the condition.
This month’s announcements of appointments, acquisitions, new hires, and other news include Standigm, Astellas Pharma, Trialbee, and other key companies.
The company has landed funding from the Bill and Melinda Gates Foundation for research and development on a prototype of a refillable contraceptive solution.
The company reports dosing of the first subject in a Phase IIa proof-of-concept study investigating a drug for an autism spectrum disorder related condition.
The group’s latest report glimpses inside the minds of pharma leaders, who are looking at a product’s full life-cycle development at the preclinical stage.
The pharmaceutical company has inked a strategic collaboration with the drug discovery firm, centering on uncovering novel targets in Alzheimer’s disease.
Biopharmaceutical company Global Blood Therapeutics specializes in conditions that often disproportionately impact underrepresented communities, such as SCD.
The pharmaceutical company has forged a partnership with the nanotechnology specialist to use nanoparticle tech and formulation to advance its products.
This month’s announcements of appointments, partnerships, expansions, and mergers include Curia, Thread, TFF Pharmaceuticals, and other notable companies.
A leader from pharmaceutical firm Astellas discusses how the company has put to use a discovery platform that combines human expertise, AI, and robotics.
This month’s announcements of launches, appointments, and partnerships includes Saama, COTA, Yourway, Eversana, Kindeva, and other notable industry companies.
Merck (MSD outside the US and Canada) is welcoming applications from early-stage biomedical start-ups for its newly launched Merck Digital Sciences Studio (MDSS): which seeks to support technologies for drug discovery and development.
In this first of a two-part series, an expert discusses various factors behind the DCT format’s rapid rise and likely longevity in the drug development arena.
